Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome

Wen, Chao; Xie, Liping; Hu, Chenxia

doi:10.1111/jcmm.17132

Cited by 13 publications

(12 citation statements)

References 94 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The paracrine impact of stem cells is also mediated via secreted EVs ( 71 ). MSCs can release a wide spectrum of soluble factors such as secretomes into the culture medium, which are less immunogenic and tumorigenic ( 72 , 73 ). MSC paracrine activity could be classified into various activities, such as anti-apoptotic, anti-inflammatory, angiogenic, immunosuppressive, and immunomodulating impacts ( 74 ).…”

Section: Contentsmentioning

confidence: 99%

“…One of the key mechanisms of MSC-EVs in tissue regeneration is stimulation of the angiogenesis via activation of various signaling pathways ( 88 , 89 ). The MSC-EVs urinary bladder wall diseases therapeutic activities are mediated via the bladder tissues regeneration and suppression of inflammation, which helps to prevent disease development and recurrence ( 73 ). Besides the possible effects of the purified EVs in the treatment of bladder diseases, we will also explain examples of the roles of stem cell conditioned medium (CM) or co-culture platforms in bladder disease therapy that represent the paracrine action of stem cells in which EVs are potently involved.…”

Section: Contentsmentioning

confidence: 99%

See 1 more Smart Citation

New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome

Dayem

Song

Lee

et al. 2022

BMB Rep

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disorder characterized by suprapubic pain and urinary symptoms such as urgency, nocturia, and frequency. The prevalence of IC/BPS is increasing as diagnostic criteria become more comprehensive. Conventional pharmacotherapy against IC/BPS has shown suboptimal effects, and consequently, patients with end-stage IC/BPS are subjected to surgery. The novel treatment strategies should have two main functions, anti-inflammatory action and the regeneration of glycosaminoglycan and urothelium layers. Stem cell therapy has been shown to have dual functions. Mesenchymal stem cells (MSCs) are a promising therapeutic option for IC/BPS, but they come with several shortcomings, such as immune activation and tumorigenicity. MSC-derived extracellular vesicles (MSC-EVs) hold numerous therapeutic cargos and are thus a viable cell-free therapeutic option. In this review, we provide a brief overview of IC/BPS pathophysiology and limitations of the MSC-based therapies. Then we provide a detailed explanation and discussion of therapeutic applications of EVs in IC/BPS as well as the possible mechanisms. We believe our review will give an insight into the strengths and drawbacks of EV-mediated IC/BPS therapy and will provide a basis for further development.

show abstract

Section: Contentsmentioning

confidence: 99%

Section: Contentsmentioning

confidence: 99%

New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome

Dayem

Song

Lee

et al. 2022

BMB Rep

View full text Add to dashboard Cite

show abstract

“…Conversely, SCs in adults are considered limited in their developmental and regenerative potential, typically to the tissues where they reside, despite the current findings that some adult SCs have SC plasticity, similar to the biological potential of ESCs. Namely, very primitive BM-derived cells, such as very small embryonic-like SCs (VSELs), are also able to develop into a variety of somatic cells, due to the aforementioned SC plasticity [2,[26][27][28][29][30][31][32][33][34].…”

Section: Embryonic Stem Cellsmentioning

confidence: 99%

“…Naime, vrlo primitivne ćelije potekle iz kostne srži, kao što su veoma male MĆ nalik embrionalnim (engl. very small embryonic-like SCs -VSELs), takođe imaju sposobnost da se razviju u razne somatske ćelije, zahvaljujući već spomenutoj plastičnosti MĆ kojom se odlikuju [2,[26][27][28][29][30][31][32][33][34].…”

Section: Embrionalne Matične ćElijeunclassified

“…Despite strong ethical arguments that ESC research, and especially potential clinical use, border on negligent manslaughter [3,5], ESCs are the most promising potentially transplantable SCs. Namely, basic research and some preclinical investigations with ESCs have proven to be important for the development of new cell-replacement methods and strategies to restore damaged tissues and re-establish critical functions of the diseased human body [2,[26][27][28][29][30][31][32][33][34].…”

Section: Embrionalne Matične ćElijementioning

confidence: 99%

See 1 more Smart Citation

A stem cell overview: From evolving hemobiological concepts to (auto)grafting in clinical practice

Balint¹,

Pavlović²,

Marković³

et al. 2022

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

Conventional hematopoietic stem cell transplantation is a well-known treatment method for numerous acquired and congenital hematopoietic disorders, disorders of the immune system, as well as certain metabolic disorders. Stem cells (SCs) can be defined as cells capable of self-renewal with a high proliferative capacity and the potential to differentiate into functionally competent mature cells. Stem cells can be divided into embryonic SCs (ESCs) and tissue-specific or adult SCs - such as bone marrow (BM) stem cells, peripheral blood (PB) stem cells, and SCs derived from umbilical cord blood (UCB), as well as other non-hematopoietic or somatic SCs. SCs in adults are characteristically considered to be restricted in their regenerative and differentiative potential, while embryonic stem cells are 'true' totipotent/pluripotent cells, due to their ability to develop into endoderm, ectoderm, or mesoderm - all three embryonic tissue types in the human body. They are the most promising, but also the most controversial type of potentially transplantable SCs. Immature hematopoietic SCs have the potential of differentiating, not only into all blood cells, but also into some somatic cell types (SC plasticity). In different clinical settings, the transplantation of immature stem cells leads to the repopulation of recipient bone marrow, with subsequent complete, stable, and long-term reconstitution of hematopoiesis. Given that immature stem cells are also capable of homing to different tissues, autologous stem cell implantation into a damaged and/or ischemic area induces their colonizing and consecutive transdifferentiating into cell lineages of the host organ, including neovascularization. Thus, they are clinically applicable in the field of regenerative medicine for the treatment of myocardial, brain, vascular, liver, pancreatic, and other tissue damage. The purpose of this overview is to recapitulate the key developments in the rapidly evolving area of stem cell research, as well as to review the use of SCs in conventional transplantations and in regenerative medicine. Additionally, a brief critical evaluation of our own stem cell research will be summarized.

show abstract

Mesenchymal stem cell‐derived exosomes in myocardial infarction: Therapeutic potential and application

Li,

Tang,

Yin

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

Myocardial infarction refers to the irreversible impairment of cardiac function resulting from the permanent loss of numerous cardiomyocytes and the formation of scar tissue. This condition is caused by acute and persistent inadequate blood supply to the heart's arteries. In the treatment of myocardial infarction, Mesenchymal stem cells (MSCs) play a crucial role because of their powerful therapeutic effects.These effects primarily stem from the paracrine secretion of multiple factors by MSCs, with exosome‐carried microRNAs being the most effective component in promoting cardiac function recovery after infarction. Exosome therapy has emerged as a promising cell‐free treatment for myocardial infarction as a result of its relatively simple composition, low immunogenicity and controlled transplantation dose. Despite these advantages, maintaining the stability of exosomes after transplantation and enhancing their targeting effect remain significant challenges in clinical applications. In recent developments, several approaches have been designed to optimize exosome therapy. These include enhancing exosome retention, improving their ability to target specific effects, pretreating MSC‐derived exosomes and employing transgenic MSC‐derived exosomes. This review primarily focuses on describing the biological characteristics of exosomes, their therapeutic potential and their application in treating myocardial infarction.

show abstract

Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome

Cited by 13 publications

References 94 publications

New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome

New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome

A stem cell overview: From evolving hemobiological concepts to (auto)grafting in clinical practice

Mesenchymal stem cell‐derived exosomes in myocardial infarction: Therapeutic potential and application

Contact Info

Product

Resources

About